A Safety Extension Study in Patients With Erythropoietic Protoporphyria (EPP)
NCT04578496
·
clinicaltrials.gov ↗
PHASE3
Phase
COMPLETED
Status
16
Enrollment
INDUSTRY
Sponsor class
Conditions
Erythropoietic Protoporphyria
Interventions
DRUG:
Afamelanotide
Sponsor
Clinuvel Pharmaceuticals Limited